| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | Director
2 companies
Stephen Davis last filed a Form 4 in August 2024, as CEO at ACAD. The filings on record cover 2 companies. Stephen Davis's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Stephen Davis's trades have earned a middling insider score of 68/100 across 21 rated trades. Over a 12-month horizon, 76.2% of those trades were profitable, with an average 12-month return of +7.7%.
At the last filing, the largest reported position was 186,555 shares of ACAD. The ACAD filings lean toward selling, a net 901,217 shares.
Stephen Davis has 46 Form 4 filings on record from March 2015 to August 2024, across 2 companies: CEO at Acadia Pharmaceuticals (ACAD), 2015–2024; Director at Heron Therapeutics (HRTX), 2019–2022.
The 103 reported transactions were 38 open-market sales, 32 option or other derivative awards, 26 option exercises and 7 stock awards.
Counted by filing, the open-market trades come to no purchases and 27 sales worth about $33.2M.
The largest open-market sale was 200,000 shares of ACAD at an average $46.02 on May 14, 2020, about $9.2M.
2 of the 11 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 9 were not.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2024 | ACAD Acadia Pharmaceuticals Inc | CEO | Sell | 31,747 | $15.28 | $485,094.16 | -14.5% | +8.1% | +58.4% | |
| May 2, 2024 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 11,427 | $16.94 | $193,573.38 | -6.9% | +11.4% | -12.7% | |
| Apr 8, 2024 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 26,574 | $17.87 | $474,877.38 | -15.6% | -8.3% | -20.8% | |
| Mar 27, 2024 | ACAD Acadia Pharmaceuticals Inc | CEO | Sell | 17,714 | $17.90 | $317,080.60 | -13.0% | -14.3% | -5.5% | |
| Feb 26, 2024 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 5,577 | $24.67 | $137,584.59 | -5.2% | -41.7% | -26.6% | |
| Jan 8, 2024 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 3,732 | $29.96 | $111,810.72 | -3.7% | -40.9% | -42.3% | |
| Oct 6, 2023 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 51,563 | $21.96 | $1,132,323.48 | -36.6% | +38.1% | -30.4% | |
| Jul 14, 2023 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE10b5-1 | 100,000 | $30.04 | $3,004,350.00 | -73.2% | -29.6% | -44.8% | |
| Jul 12, 2023 | ACAD Acadia Pharmaceuticals Inc | CEO | Sell10b5-1 | 71,602 | $25.04 | $1,792,898.88 | -66.1% | -9.4% | -31.7% | |
| May 1, 2023 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 7,806 | $21.18 | $165,331.08 | -6.7% | +34.4% | -23.2% |